Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens
| Autor: | A. K. Blystad, Stein Kvaløy, Jan Delabie, Grete F. Lauritzsen, Jens Hammerstrøm, Sigbjørn Smeland, Ida Münster Ikonomou, Harald Holte, Gunnar Kvalheim |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Pediatrics Adolescent medicine.medical_treatment Cancer Care Facilities CHOP Transplantation Autologous medicine Humans Progression-free survival Survival rate Aged Neoplasm Staging Retrospective Studies Chemotherapy Antibiotics Antineoplastic Norway business.industry Hematology Middle Aged medicine.disease Burkitt Lymphoma Survival Analysis Chemotherapy regimen Surgery Survival Rate Transplantation Regimen Methotrexate Treatment Outcome Oncology Doxorubicin Female business Burkitt's lymphoma Stem Cell Transplantation |
| Zdroj: | Annals of Oncology. 15:1072-1078 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdh262 |
| Popis: | Background: Burkitt’s/Burkitt-like lymphoma (BL/BLL) are highly aggressive lymphomas mainly affecting children and young adults. We report the results in adolescent and adult patients with the use of three successive regimens. Patients and methods: Forty-nine patients aged 15 –70 years admitted to the Norwegian Radium Hospital in the period 1982– 2001 with a diagnosis of BL/BLL on histological review and who were given chemotherapy with curative intent are included in this analysis. Up to 1987 patients were given doxorubicin-based chemotherapy supplemented with intravenous and intrathecal methotrexate (MmCHOP). From 1987 to 1994, patients who obtained complete remission upon this regimen were consolidated with high-dose therapy with stem-cell support (MmCHOP + HDT). In 1995 we introduced as frontline therapy the German Berlin – Frankfurt– Munster (BFM) regimen. Results: By intention to treat analyses, the progression-free survival rates for patients who received MmCHOP (n = 13), MmCHOP + HDT (n = 17) or BFM therapy (n = 19) are 30.8%, 70.6% and 73.7%, respectively. In the groups of patients who received either the BFM regimen or MmCHOP + HDT, all patients who obtained complete remission upon induction therapy are continuously disease free. There was no treatment-related death. Conclusions: BL/BLL in adolescents and adults can successfully be treated with 5-day blocks of intensified chemotherapy such as the BFM regimen or CHOP/methotrexate-based chemotherapy consolidated with high-dose therapy. Using the BFM regimen, continuous remissions are obtained without additional myeloablative chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|